MBK-01 is an investigational medicinal product being tested in this clinical trial. It comes in the form of oral capsules and is designed to help people with recurrent diverticulitis, a condition where small bulges or pockets in the digestive tract become inflamed or infected. The goal of MBK-01 is to reduce the number of times these painful episodes occur. It works by using a special blend of intestinal microbiota, which are beneficial bacteria that live in the gut. These bacteria can help maintain a healthy balance in the digestive system, potentially reducing inflammation and preventing future episodes of diverticulitis. The trial is also looking at how safe and tolerable MBK-01 is for patients, as well as finding the best way to use it for treatment.

Recurring Diverticulitis – Recurring diverticulitis is a condition characterized by repeated inflammation or infection of small pouches, called diverticula, that can form in the walls of the digestive tract, particularly the colon. These pouches develop when weak spots in the intestinal wall give way under pressure, causing small bulges. When these diverticula become inflamed or infected, it leads to diverticulitis, which can cause symptoms such as abdominal pain, fever, and changes in bowel habits. The inflammation can lead to complications like abscesses, perforations, or blockages in the colon. Over time, repeated episodes of diverticulitis can cause scarring and narrowing of the colon. The condition often requires careful management to prevent further episodes and maintain digestive health.